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Abstract
Background MRI of the lung is recommended in a number
of clinical indications. Having a non-radiation alternative is
particularly attractive in children and young subjects, or
pregnant women.
Methods Provided there is sufficient expertise, magnetic
resonance imaging (MRI) may be considered as the prefer-
ential modality in specific clinical conditions such as cystic
fibrosis and acute pulmonary embolism, since additional
functional information on respiratory mechanics and region-
al lung perfusion is provided. In other cases, such as
tumours and pneumonia in children, lung MRI may be
considered an alternative or adjunct to other modalities with
at least similar diagnostic value.
Results In interstitial lung disease, the clinical utility of MRI
remains to be proven, but it could provide additional infor-
mation that will be beneficial in research, or at some stage in
clinical practice. Customised protocols for chest imaging
combine fast breath-hold acquisitions from a “buffet” of
sequences. Having introduced details of imaging protocols
in previous articles, the aim of this manuscript is to discuss
the advantages and limitations of lung MRI in current clinical
practice.
Conclusion New developments and future perspectives
such as motion-compensated imaging with self-navigated
sequences or fast Fourier decomposition MRI for non-
contrast enhanced ventilation- and perfusion-weighted imaging
of the lung are discussed.
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Main Messages
• MRI evolves as a third lung imaging modality, combining
morphological and functional information.
• It may be considered first choice in cystic fibrosis and
pulmonary embolism of young and pregnant patients.
• In other cases (tumours, pneumonia in children), it is an
alternative or adjunct to X-ray and CT.
• In interstitial lung disease, it serves for research, but the
clinical value remains to be proven.
•New users are advised to make themselves familiar with the
particular advantages and limitations.
Keywords Magnetic resonance imaging . Cystic fibrosis .
Pulmonary embolism . Tumor . Infiltrate . Functional
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Introduction
Magnetic resonance imaging (MRI) of the lung has
been a challenge due to limitations such as low proton
density in the lung and the fast signal decay due to
susceptibility artefacts at air-tissue interfaces. Thanks to
recent technical advances such as parallel imaging,
shared echo-technique and rotating phase encoding, lung
MRI can be recommended in a number of clinical
indications [1].
The introduction into clinical routine is facilitated by
customising comprehensive MR protocols that apply fast
breath-hold acquisition techniques from a “buffet” of
sequences that are optimised for chest imaging [2]. The
basic imaging protocol comprises a non-contrast-enhanced
protocol based on fast breath hold T1- and T2-weighted
sequences to detect lung infiltrates, nodules or masses.
Additional steady-state free precession sequence (SSFP)
imaging can be performed with free breathing and is highly
sensitive for detection of central pulmonary embolism, and
provides information on respiratory mechanics [2, 3].
Respiration-triggered T2-weighted sequences are available
for uncooperative patients and those with breath-holding
difficulties [4]. The sensitivity of this basic protocol for
infiltrates and lung nodules is reported to be similar to CT
[5–7]. Additional contrast-enhanced fat-saturated three-
dimensional gradient echo (3D-GRE) sequences are war-
ranted for unclear masses, consolidations or pleural effusion
detected in the basic protocol [8]. Three components are
available for the assement of pulmonary vasculature and
lung perfusion: An initial free-breathing unenhanced exami-
nation followed by dynamic contrast-enhanced perfusion im-
aging and a high-resolution angiogram [9].
With these customised protocols, lung MRI offers alter-
native solutions to routine diagnostic challenges, in particu-
lar for the imaging of the mediastinum. It also provides an
alternative radiation-free diagnostic option that is especially
relevant to young and pregnant patients, as well as subjects
who need to undergo multiple investigations, e.g. for re-
search purposes.
The details of the MR physics background as well as
the protocol tree and its branches have been addressed
in the two preceeding articles (citations 1/3 and 3/3).
The aim of this paper is to discuss the advantages and
limitations of lung MRI for a number of selected clinical
applications and to outline current developments and future
perspectives.
Clinical scenarios in which MRI might be considered
a first choice modality
Cystic fibrosis
Cystic fibrosis (CF) lung disease is caused by mutations in
the CFTR gene and remains one of the most frequent lethal
inherited diseases in the Caucasian population. Due to the
progress in therapy and management of CF lung disease in
the past decades, the life expectancy of CF patients has
increased substantially, with a current median survival of ap-
proximately 40 years and is expected to increase even further
[10, 11]. It is known that clinical parameters including
spirometric pulmonary function testing (PFT) suffer from
limited sensitivity and provide no regional information.
With the advances in imaging in general and the ability to
characterise and quantify CF in greater detail, imaging will
likely play an increasing role in the improved understanding
of the disease process and the progression of disease. Fur-
thermore imaging will serve as a biomarker for the devel-
opment of new treatments.. However, this also means that it
becomes vital to reduce the overall (cumulative) radiation
burden in this population, as this could lead to iatrogenic
carcinogenesis [12].
Magnetic resonance imaging (MRI) is reported to be
comparable to CT with regard to the detection of morpho-
logical changes in the CF lung [13–15]. At the same time
MRI is superior to CT when it comes to the assessment of
functional changes such as altered pulmonary perfusion
[16]. Moreover, using the described MR protocols, it is
possible to visualise bronchiectasis, bronchial wall thickening,
mucus plugging, air fluid levels, consolidation and segmental
consolidation and destruction [13], (Fig. 1a, b).
The accuracy of MRI in detecting bronchiectasis is de-
pendent on a number of factors, including bronchial level
and diameter, wall thickness, and the signal from within the
bronchial wall and lumen. Central bronchi and bronchiecta-
sis (central, peripheral) are well visualised on MRI, whereas
normal peripheral bronchi starting at the 3rd to 4th genera-
tion are poorly visualised. The depiction of bronchial wall
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thickening depends on bronchial size and signal [13]. A
high signal of the bronchial wall on T2-weighted (T2w)
images represents increased fluid, i.e. oedema, possibly
caused by active inflammation. Enhancement of the thick-
ened bronchial wall on post-contrast, fat-suppressed T1-
weighted images is thought to be related to inflammatory
activity. It is important to note that compared to MRI, CT
can only detect wall thickening and is not able to comment
on the cause [13].
Mucus plugging is well visualised on MRI even down to
the small airways due to the high T2 signal of its fluid
content. It is recognised as a high T2 signal filling of the
bronchus along its course with branching in the periphery
giving a grape-like or tree-in-bud appearance, respectively.
As mucus plugs do not enhance, they are easily differenti-
ated from bronchial wall thickening [13].
Bronchial air fluid levels are indicative of active infection,
occurring in saccular or varicose bronchiectasis, and can be
visualised by their high T2 signal. However, discriminating a
bronchus with an air fluid level from one with partial mucus
plugging or a severely thickened wall can be difficult. When
evaluating the signal characteristics on T2- and T1-weighted
images with and without contrast enhancement, air fluid levels
can usually be differentiated.
Pulmonary consolidation in CF is mainly caused by
alveolar filling with inflammatory material leading to a high
signal on T2w images. Comparable to CT, MRI is able to
visualise air bronchograms as low signal areas following the
course of the bronchi within the consolidation [17, 18]. With
progression of the disease, complete destruction of lung
segments or lobes can occur with similar appearances on
MRI and CT.
Compared to CT, the strength of MRI is the additional
assessment of “function”, i.e. perfusion, pulmonary hemo-
dynamics and ventilation. In CF, regional ventilatory defects
cause changes in regional lung perfusion due to the hypoxic
vasoconstriction response or tissue destruction. Using MRI,
lung perfusion can be assessed by contrast-enhanced lung
perfusion imaging [19]. Using contrast-enhanced 3D MRI,
perfusion defects in 11 children with CF were reported to
correlate well with the degree of tissue destruction [16].
Furthermore it was shown that at the age of 0–6 years lung
perfusion changes were more prominent than morphological
changes. However, establishing quantitative assessment
tools for lung morphology is challenging for several rea-
sons. First, signal intensities as derived from MRI are not
calibrated as compared to CT. Second, the signal-to-noise
ratio (SNR) in the lung is low and heterogeneous due to
several physical circumstances [20]. Moreover, due to the
lack of linearity between the MR signal and the concentra-
tion of applied contrast media, quantification of pulmonary
perfusion using MRI is challenging [21]. Nevertheless,
Risse et al. [22] described the importance of the qualitative
assessment of the contrast time course component when
analysing contrast-enhanced 3D MRI to categorise perfu-
sion changes as normal, delayed, reduced, reduced and
Fig. 1 A 29-year-old female
with cystic fibrosis. The axial
T2-weighted (BLADE; a) and
the volumetric contrast-
enhanced 3D-GRE (VIBE; b)
breath-hold acquisitions show
severe bronchiectasis, bronchial
wall thickening, mucus plug-
ging, pleural effusion as well as
a destructed middle lobe. The
perfusion subtraction image (c)
shows a severely impaired
perfusion pattern with loss of
perfusion in several areas. The
maximum enhancement (MAX)
and time to peak anhancement
(TTP maps) allow for a further
characterisation of the perfusion
impairment. Most areas with
impaired perfusion show a
reduced (MAX map) and delaid
(TTP map) perfusion. Notice the
area in the left upper lobe with
reduced but not delayed
perfusion (arrowhead)
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delayed as well as perfusion loss [22]. Using dedicated post-
processing tools, these data can be displayed in 3D [23],
(Fig. 1c, d, e).
In addition to quantitative and qualitative scoring methods,
clinical practice relies on visual assessment. It should be
feasible to introduce anMR scoring system that is comparable
to CT [24–26]. Up to now published studies either used a
modified Brody [15] or an adapted Bhalla/Helbich score
[14]. None of theses scores was tested for reproducibility.
Besides morphology, functional parameters are important
for a comprehensive diagnosis and have to be integrated
into a dedicated MR score, also to generate an additional
benefit over CT. A recently presented morpho-functional
MRI score is easily applicable and reproducible for the
semi-quantitative morphological and functional evaluation
of a large severity spectrum of CF lung disease [27].
Based on the current state of affairs, perfusion MRI can
be applied to monitor therapy and may be capable of differ-
entiating between regions with reversible and irreversible
disease. In contrast to CT [24–26, 28, 29] a dedicated
scoring system as well as quantitative readouts for pulmo-
nary MRI is lacking and will require development.
Acute pulmonary embolism in young or pregnant patients
The current imaging reference technique in evaluation of acute
pulmonary embolism is helical computed tomography [30]. Its
major advantage over ventilation and perfusion scintigraphy
and SPECT are the availability and the comparably short
acquisition time of the study with almost immediate delivery
of the necessary information for patient care [30]. However,
radiation exposure by CT is significant; therefore an alter-
native method for young patients and pregnant women
would be appreciated. To be competitive with CT, an abbre-
viated MR protocol focusing on lung vessel imaging and lung
perfusion may be accomplished within 15 min in-room time.
Although MR angiography has been demonstrated as an
excellent tool in dedicated centres [31], more recent data
from a large multicentre study suggest that the technique in
isolation produced unsatisfactory results [32]. Therefore,
combinations of different available MRI techniques for the
detection of pulmonary embolism may be of better value
[33]. This protocol was further modified and extended into a
two-step algorithm [9]. As a first step, a steady-state GRE
sequence acquired in two or three planes during free breathing
would serve for an early detection of large central emboli
within the first 5 min of the examination—according to the
literature with a sensitivity of 90% and a specificity of close to
100% [33–35]. Any patient with a massive, central embo-
lism detected at this point could be directly referred to
intensive care and treatment; the time to diagnosis would
be at least as short as with contrast-enhanced helical CT. If
this first step of the examination produces a negative or
unclear result, the protocol would be continued with the
contrast-enhanced steps including first pass perfusion imag-
ing, high spatial resolution contrast-enhanced (CE) MRA
Fig. 2 A 55-year-old patient
with acute pulmonary embolism.
Coronal steady-state free
precession images acquired
during free breathing (a) and
contrast-enhanced coronal 3d
flash angiogram acquired in
breathhold (b; embolus inside
the right lower lobe artery
circled); c series of subtracted
images from the first pass
perfusion study, perfusion
deficits marked with open
arrows at the image obtained
at peak lung enhancement;
1.5-T MRI scanner
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and a final acquisition with a volumetric interpolated 3D
FLASH sequence in transverse orientation (Fig. 2). Despite
its composition of multiple sequences, the two-step exami-
nation could be completed within 15 min in-room time,
which makes it feasible as a quick test for daily clinical
routine. In many cases, such as in pregnant woman, when
administration of contrast material or radiation exposure is
contra-indicated, the examination can be limited to the first
step, the free breathing or breathhold acquisition of steady-
state GRE sequences alone. Furthermore, since these steps
are partially redundant, at least one acquisition would be
expected to be diagnostic even in non-compliant patients.
Lung MRI as an alternative or adjunct
to other modalities
Central mass with atelectasis and pleural effusion
Undoubtedly, contrast-enhanced multiple detector row com-
puted tomography is the method of first choice in imaging
thoracic malignancies. MRI is considered as an alternative
method, e.g. when the application of iodinated contrast
media is contraindicated. For this purpose, MRI with dedicated
standard protocols can provide a comprehensive morphologic
TNM evaluation [36]. A contrast-enhanced examination can
be achieved within 25 min in-room time. Intra-pulmonary
masses larger than the clinically relevant size of 4–5 mm in
diameter can be easily detected. The extent of mediastinal,
hilar and supraclavicular lymph node enlargment can be
assessed with excellent soft tissue contrast. Metastatic dis-
ease involving the liver, the adrenal glands and the skeleton
of the thorax are fully covered. The feasibility of extending
the examination to whole-body staging with comparable
results as achieved by PET/CT has been demonstrated
[37–40]. The only limitation compared to CT is the detec-
tion of nodules smaller than the clinically relevant size of 4–
5 mm. Beyond being just a surrogate for a CT scan in some
cases, MRI can offer additional advantages. In large pulmo-
nary masses, the excellent soft tissue contrast of MRI allows
for the distinction of tumour from atelectasis and pleural
effusion, e.g. for image-guided radiotherapy planning. Ad-
ministration of T1-shortening contrast material specifically
contributes to detecting tumour necrosis, chest wall or me-
diastinal invasion, and pleural reaction/carcinomatosis [8]
(Fig. 3). Furthermore, MRI contributes comprehensive func-
tional information on respiratory mechanics, tumour mobil-
ity [41] and lung perfusion [42, 43]. The clinical value of
complementing the purely morphologic staging by imaging
of perfusion and tumour motion in specific clinical settings
and situations has been demonstrated and is subject to
further investigation.
Pneumonia in young patients
The potential of MRI to replace chest radiography, particu-
larly in very young children, was already investigated several
years ago [18, 44–46]. Much of this work was conducted on
low-field MRI (mainly 0.2-T scanners) using steady-state
free precession sequences [47]. On average, three thick
slices are acquired in coronal orientation with a mean
breathhold time of 4–5 s. However, nowadays, only a few
institutions regularly use low-field lung MRI in paediatric
Fig. 3 A 56-year-old female patient with small cell lung cancer. The
transverse T2-weighted fat-saturated (a) and T1-weighted contrast-
enhanced fat-saturated 3D-GRE images (b, c) show a large, centrally
necrotic mass in the left upper lobe with large peri-hilar lymph node
metastases. Note the high soft tissue contrast between alelectatic lung
(open arrow), small rim of solid tumour (filled arrow) and colliquated
central portion of the mass (asterisk)
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radiology. Nevertheless, the experience from this work may
be considered valid for the suggested protocols for 1.5-T
scanners since image quality has significantly improved.
Therefore, T2-weighted fat-suppressed as well as dynamic
contrast-enhanced T1-GRE sequences are applied with a
slice thickness between 5 and 6 mm [48]. Disease entities
encompassing community-acquired pneumonia, empyema,
fungal infections and chronic bronchitis are detectable [49]
(Fig. 4).
Recent studies demonstrated the feasibility of chest
examinations on 3-T high-field MRI. ECG triggering seems
to be mandatory to reduce pulsation artefacts. One study
used the navigator techniques to reduce breathing artefacts.
High-field chest MRI may allow differentiation between
inflammation- and fibrosis-predominant lesions in UIP and
NSIP in adult patients [50]. Moreover, a recent comparison
between 3-T lung MRI and HRCT as gold standard showed
an excellent correlation with non-cystic fibrosis chronic
lung disease in children [51]. Breathhold T2- as well as
T1-weighted sequences with ECG triggering were acquired.
In summary, lung MRI may prove to become a valuable tool
for detection as well as characterisation of inflammatory
lung disease in children.
Clinical scenarios in which CT remains the first choice
modality
Emphysema/COPD
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality worldwide. At
present it is the fourth most common cause of death among
adults, but its prevalence is increasing [52]. COPD is charac-
terised by incompletely reversible airflow obstruction due to
a mixture of airway obstruction (obstructive bronchiolitis)
and parenchymal destruction (emphysema) [52]. Severity of
COPD is clinically assessed by lung function tests and
diffusion capacity for carbon monoxide. CT is considered
the reference standard for imaging COPD-related morpho-
logical changes. Imaging COPD with proton MRI is a major
challenge due to the loss of lung tissue and reduced blood
volume due to hypoxic vasoconstriction combined with
hyperinflation, all resulting in a marked reduction of lung
parenchymal signal [53]. The strength of MRI for imaging
COPD lies with the assessment of functional parameters like
perfusion and respiratory dynamics [54].
In COPD emphysematous destruction is difficult to diag-
nose because of a loss of MR signal. Hyperinflation severely
affects diaphragmatic geometry with subsequent reduction
of the mechanical properties, while the accessory neck and
rib muscles become less effective [55]. The common clinical
measurements of COPD do not provide insights into how
structural alterations in the lung lead to dysfunction in the
breathing mechanics, although treatments such as lung volume
reduction surgery (LVRS) are thought to improve lung func-
tion by facilitating breathing mechanics and increasing elastic
recoil [56].
In contrast to normal subjects with regular, synchronous
diaphragm and chest wall motion, patients with emphysema
frequently have reduced, irregular or asynchronous motion,
with a significant decrease in the maximum amplitude and
Fig. 4 A 13-year-old girl with suspected organising pneumonia
(BOOP) in both lungs. Transverse T2-weighted TSE images (a) were
acquired with the navigator technique (sample volume placed on the
dome of the right liver lobe). The open arrow indicates an oval-shaped
consolidation with pleural contact in the lower left lobe and moderate
signal intensity. Coronal contrast-enhanced fat-saturated T1-weighted
GRE images (b) were acquired with the breathhold technique. The
open arrow indicates the oval-shaped consolidation in the lower left
lobe with contrast enhancement; this is interpreted as an indicator of an
active inflammatory process
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the length of apposition of the diaphragm [57]. In some
patients the diaphragm movement is not coordinated (e.g.
the ventral portion of the hemidiaphragm moves inferiorly
while the dorsal part moves cranially [58]), while paradoxical
diaphragmatic motion correlated with mild and moderate
hyperinflation [59].
One study demonstrated a correlation between the change
of parenchymal signal intensity measured by MRI at inspi-
ration and expiration and FEV1 (r00.508) as a predictor of
airflow obstruction [60].
Several studies have shown that airway obstruction in
patients with COPD tends to be located in airways smaller
than 2 mm internal diameter [61]. These airways are located
between the 4th and the 14th generation of the tracheobron-
chial tree. Severe peripheral airflow obstruction also affects
the proximal airways from subsegmental bronchi to trachea.
For the assessment of tracheal instability, such as seen in
tracheobronchial malacia (which may mimick the clinical
appearance of small airways disease), MR cine acquisitions
during continuous respiration or forced expiration can be
recommended [62]. The depiction of airway dimensions and
size of the airway walls by MRI in physiological condition
is limited to the central bronchial tree. For the depiction of
bronchiectasis, sequences with a high spatial resolution are
essential (see section on CF). The previously described 3D
volume interpolated gradient echo sequence (VIBE) offers a
sufficient spatial resolution with a sensitivity of 79% and a
specificity of 98% regarding visual depiction of bronchiec-
tasis compared to CT [3].
Gas exchange in the lungs is optimally maintained by
matching of ventilation and perfusion. In patients with
COPD, ventilation is impaired due to airway obstruction
and parenchymal destruction. In regions with reduced ven-
tilation, hypoxic vasoconstriction occurs [63, 64] causing a
reduction of local pulmonary blood flow with redistribution
to better ventilated lung regions [65, 66]. The reduction of
the pulmonary vascular bed is related to the severity of
parenchymal destruction; however the distribution of perfu-
sion does not necessarily match parenchymal destruction
[67, 68]. Conventional radionuclide perfusion scintigraphy
has been used to assess these abnormalities, but it has
substantial limitations with respect to spatial and temporal
resolution.
MR perfusion allows for a high diagnostic accuracy in
detecting perfusion abnormalities of the lung [69, 70]. Ad-
ditionally, MR perfusion ratios correlate well with radionu-
clide perfusion scintigraphy ratios [71, 72]. Lobar and
segmental analysis of the perfusion defects can be per-
formed [68]. Perfusion abnormalities in COPD clearly differ
from those caused by vascular obstruction. While wedge-
shaped perfusion defects occur in embolic obstruction, a
generally low degree of inhomogeneous contrast enhance-
ment is found in COPD with emphysema [73]. Furthermore,
the peak signal intensity is reduced. These features allow for
easy visual differentiation and compare well with work done
using CT perfusion experiments [74]. In patients with
COPD the quantitative evaluation of 3D perfusion showed
that the mean pulmonary blood flow (PBF), pulmonary
blood volume (PBV) and mean transit time (MTT) are
diffusely decreased and the changes are heterogeneous
[75]. Calculated mean PBF and PBV are significantly de-
creased, and MTT is significantly shortened [76].
Interstitial lung disease
Interstitial lung disease (ILD) encompasses numerous patho-
logic disorders of different etiologies, generally manifesting
with an inflammatory reaction known as “alveolitis”, which
may progress towards fibrosis. Because the nature of these
disorders is highly heterogeneous, imaging findings alone are
often insufficient for making the final diagnosis, and integra-
tion of morphologic aspects with clinical and functional data
is required. In the last 3 decades, computed tomography (CT)
has clarified the elementary alterations and morphologic pat-
terns characterising the infiltrative changes of ILD. In con-
trast, MRI has only recently overcome many of the technical
issues related to lung imaging, providing a standardised image
quality, which in many instances is now comparable to CT.
This partly explains the relatively limited number of MRI
studies that have been clinically performed in ILD patients.
Nonetheless, published data suggest at least three possible
applications for lung MRI in ILD: (1) visualisation and rec-
ognition of morphological changes and their patterns, (2)
assessment of the inflammatory activity of the disease and
(3) effects of lung morphologic changes on functional parame-
ters such as contrast enhancement and perfusion.
The essential morphologic findings in ILD include air-
space disease, interstitial abnormalities or a combination of
the two. BecauseMR signal increases proportionally to proton
density, air-space infiltrates appear on the T2-weighted images
as hyperintense areas against the dark background of the
normal lung parenchyma. When pulmonary vascular mark-
ings are not obscured, these areas can be assimilated to the
ground-glass opacities detected by CT [17, 77]. More dense
opacities appear as consolidations, which can be easily
assessed by MRI [78]. Similar to consolidations, interstitial
abnormalities increase signal intensity presenting with cur-
vilinear bands, nodules and reticulations, which can be
associated to a variable degree of parenchymal distortion
[50, 79, 80]. Fibrotic changes that extensively involve both
peripheral and perihilar portions of the lung are generally
well demonstrated on T2-weighted images, albeit that one
needs to consider extracellular interstitial water as a poten-
tial differential diagnosis in patients with suspected conges-
tive heart failure. Subtle changes in the subpleural regions
may become more difficult to visualise, notably when
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parenchymal distortion is not present, demonstrating the su-
periority of CT in this respect. T1-weighted VIBE images
offer higher spatial resolution, and post-contrast acquisition
with fat-suppression is recommended to increase the signal of
altered subpleural lung tissue against a background repre-
sented by chest wall muscles, ribs and normal lung parenchy-
ma. Honeycombing, which manifests with reticular changes
and irregular cystic transformation of the lung, can also be
assessed using this technique [50] (Figs. 5, 6, 7 and 8).
Differentiation of active inflammation from fibrosis is of
significant clinical importance both for the prediction of
therapy response and clinical outcome of ILD. Both MR
signal and contrast-enhancement characteristics of inflam-
mation and fibrosis have been investigated. Although initial
studies performed on 1.5 T lacked sufficient image quality
[81–83], the feasibility of the assessment of disease activity
in ILD was demonstrated. Only recently, 3.0-T MRI has
increased sensitivity to changes in proton density. In partic-
ular, Yi et al. [50] reported that MR signal of inflammatory
and fibrotic lesions on T2-weighted images is hyperintense
and isointense, respectively, compared to the signal from
chest wall muscle, indicating an increased water content in
the areas of inflammation.
Dynamic MRI using iv contrast administration also indi-
cated that early enhancement and washout with discernible
peak enhancement at 1 or 3 min after contrast injection was
associated with positive and negative prediction values of
82 and 92%, respectively, in predicting disease activity [50].
The earlier enhancement and rapid washout would be in
agreement with higher permeability of capillaries in the
areas of inflammation compared to those of fibrosis.
A different approach to differentiating active inflammation
from fibrosis was attempted in a recent study in a bleomycin-
induced lung injury model in rats [84]. Proton density and T2
relaxation were computed regionally in the injured lungs,
and MR-derived parameters were compared to postmortem
measures of water and collagen content. The authors con-
cluded that proton density and T2 relaxation data acquired
using MRI were sensitive to inflammation and fibrotic
changes in the lung. Although they were able to distinguish
diseased lungs as effectively as postmortem measurements,
they were unable to differentiate between fibrosis and in-
flammation. In conclusion, these data are encouraging and
support potential future applications of MRI in interstitial
lung disease both in research and clinical settings.
Future perspectives
Significant efforts have been made to further improve ro-
bustness and reproducibility of lung MR image quality.
Compared with x-ray and CT, the quality of lung MRI is
more dependent on the ability of patients to follow breath
hold instructions. Advanced acquisition schemes with inher-
ent correction of respiratory motion and cardiac pulsation
are therefore important for future developments. For exam-
ple, a conjoint research group of medical physics and
radiology departments supported by the German Research
Foundation (Deutsche Forschungsgemeinschaft) is currently
working on the development of self-navigated sequence
designs and radial k-space methods for the assessment of
lung morphology on free breathing. Similarly, a group of
Fig. 5 Infiltrative disorder of
the lung. Typical fibrotic
changes in a patient with inter-
stitial pulmonary fibrosis.
Extensive reticulation and archi-
tectural distortion predominant
in the subpleural regions of the
lung are well demonstrated by
the axial (a, b) and coronal (c–e)
MR images obtained using the
half-Fourier single-shot fast spin
echo (a, c, e) and post-constrast
volume interpolated T1-
weighted GRE (b, e) sequences
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scientists in the USA is working on dedicated MR imaging
in COPD within the Multi Ethnic Study of Atherosclerosis
consortium with particular focus on perfusion and dynamic
assessment.
One way to improve the robustness of lung MRI against
respiratory motion is to implement self-navigation. The
prototype 3D-MRI sequence (a self-navigated T1-weighted
3D flash with quasi-random k-space ordering) acquires mul-
tiple full lung volumes during free breathing, which results
in a set of images with unsharp delineation of structures that
are subject to respiratory motion. With each acquisition non-
spatially encoded DC signals are acquired at the center of k-
space to be used as navigator. This signal contains sufficient
information to detect motion and to select image
information of the different acquisitions to either produce
one motion corrected data set for morphologic imaging
without patient compliance or to perform a detailed motion
analysis [85]. Another approach is based on radial im-
aging with k-space weighted image contrast (KWIC).
Again, redundant data are acquired over multiple respiratory
cycles. Motion correction is achieved by radial data acqui-
sition with extraction of the signal from k-space centre for
the determination of the respiratory cycle. The views are
then grouped and images are reconstructed for each respira-
tory phase. Further improvements of image quality are
achieved with autofocusing, 3D image correlation, K-
space-weighted image contrast (KWIC) and principal com-
ponent analysis [86–88].
Fig. 6 Subtle subpleural reticulation in a patient with fibrotic-
predominant NSIP. The interlobular reticulation (thin arrows) is more
evident after contrast administration (c and f). A perfusion defect
(arrowhead in e) is associated to the peripheral fibrotic changes at
the left lateral costo-phrenic angle (arrowheads in d and f)
Fig. 7 Fibrosis associated with
rounded consolidation. a) Sub-
pleural reticular changes are
visualised at the periphery of the
lungs (thin arrows). b) After
contrast administration the sub-
tle linear enhancement at the
pulmonary-chest wall interface
indicates abnormal findings re-
lated to subpleural fibrosis (thin
arrows). A rounded consolida-
tion is present on the left in the
lingula suspected for lung tu-
mour in ILD (asterisk)
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Fig. 8 Bilateral hilar and medi-
astinal adenomegalies in sar-
coidosis. Node enlargement
(arrows) is demonstrated with
gradient echo images before (a)
and after administration of con-
trast material (b). Coronal per-
fusion images indicate vascular
compression at the right hilum
(arrow, c) and a wedge-shaped
perfusion defect (asterisk, d)
Fig. 9 Twenty-three year-old fe-
male with acute pulmonary em-
bolism at the time point of
diagnosis (a, b) and at follow-up
study after 6 months (c, d). The
initial dynamic contrast en-
hanced (DCE) study (a) as well
as the perfusion-weighted Four-
ier-decomposition (FD) image
(b) demonstrate multiple perfu-
sion defects (open arrows). In
the follow up study, both tech-
niques (DCE; c and FD; d)
demonstrate an almost homoge-
neous lung perfusion after ef-
fective anticoagulation
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Non-contrast-enhanced ventilation-perfusion
scanning—poor man's “have it all”?
One of the latest developments in the field of proton-based
lung MRI appears to be a very promising technology for
non-contrast-enhanced ventilation and perfusion scanning.
This novel approach, known as Fourier decomposition MRI
[89], utilises a short echo dynamic SSFP acquisition of lung
images with subsequent compensation for respiratory mo-
tion by using nonrigid image registration [90]. Spectral
analysis of the image time series allows for identification of
peaks at the respiratory and cardiac frequencies. Amplitude of
these peaks is related to regional proton density change caused
by deformation of lung parenchyma (highest signal with lowest
pulmonary air content in expiration) and pulmonary blood flow
(lowest signal with maximum blood flow in systole) [91].
Further image post-processing produces ventilation- and
perfusion-weighted maps for regional assessment of lung
function from a single acquisition series. However, the
quantitative validation remains subject to further investiga-
tion (Fig. 9) [92]. Nevertheless, there is a perspective that
the method of choice for morphologic and functional as-
sessment of acute pulmonary embolism in the very near
future might be a non-contrast-enhanced free breathing
MR scan of 10–15 min.
Hybrid PET/MRI
Hybrid PET/MRI has recently become available for clinical
research. Compared to PET/CT, PET/MRI may be advanta-
geous due to higher soft tissue contrast, while there is a
slight reduction in ionising radiation dose [93]. Technically,
integration of the two systems has been a significant chal-
lenge and required substantial modifications [94–96]. The
size of the PET detectors had to be minimised; a PET
detector that is insensitive to high magnetic fields had to
be developed, and the adverse effect of PET detector parts
on the homogeneity of the magnet’s B0 field must be mini-
mised. Moreover, interference between the radiofrequency
signals, MRI gradients and PET electronic signals must be
avoided [97]. Some of these problems were overcome by
application of optical fibres and advances in gamma ray
detector technology, which were initiated mainly by the
advent of avalanche photodiodes; in addition the routine
availability of fast scintillation materials resulted in the devel-
opment of fully magnetic-field-insensitive high-performance
PET detectors [98]. More recently, a truly integrated 3-T
MRI/PET system was launched.
Although PET/MRI may not necessarily replace the role
of PET/CT in thoracic oncological imaging [99], and spe-
cific clinical indications remain to be identified, MRI may
be advantageous when compared to CT in the investigation
of consolidating lung lesions, and malignant mediastinal
and chest wall invasion. The additional diagnostic value of
PET/MRI over PET/CT on nodal staging is questionable
since both MRI and CT nodal staging is size based [100].
MRI, however, has been reported to be of higher accuracy
than PET/CT when assessing the brain, liver and the bone
for distant metastases [101]. Oncological research may be
another potential area where multiple follow-up functional
and anatomical imaging by PET/MRI may be advantageous
over PET/CT. Lastly, with the increasing availability of
radiotracers and novel compounds for molecular and phys-
iological assessment, including labelling of target cells and
compounds that target particular cell lines or processes, the
combination of these powerful modalities may result in
significant advances for research (and potentially clinical)
purposes.
Conclusions
MRI is emerging as a valuable lung imaging modality,
together with x-ray and CT. It offers a unique combination
of morphological and functional information in a single
examination without any radiation burden to the patient.
However, although “push-button” protocols facilitate its
clinical application, lung MRI can be still challenging, being
the most comprehensive but also most expensive and least
robust of the three modalities. New users are advised to
make themselves familiar with the particular advantages
and limitations of the technique and its diagnostic scope to
appreciate its potential benefits. Given this, lung MRI will
be increasingly used and even further improved by additional
recent and future developments, in particular in the fields of
motion compensation and functional imaging.
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